Used in pharmaceutical research as a potent and selective inhibitor of Janus kinase 1 (JAK1), showing potential for treating autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its structure enables high selectivity for JAK1 over other JAK family members, which may reduce side effects commonly associated with broader JAK inhibition. Investigated for oral bioavailability and efficacy in modulating immune responses by targeting cytokine signaling pathways involved in chronic inflammation. Currently explored in preclinical and clinical development for immune-mediated conditions.